Vilya

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Retrieved on: 
星期四, 二月 1, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, ARCH Venture Partners, Senior, Corporation, GSK plc, MedImmune, Takeda Pharmaceutical Company, Knowledge, Eli Lilly and Company, Opioid, WRF, VBI Vaccines, AstraZeneca, Acquisition, Development, Epilepsy, Public, Growth, General counsel, Vilya, Corporate development, Patient, Venture round, LP, Research, Trial of the century, ARCH, Therapy, DSM-IV codes, Series

PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.

Key Points: 
  • PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.
  • In conjunction with the Series B financing, Proniras has appointed Steven Gillis, Ph.D., as Chairman and Atul Saran as an independent member to the Company’s Board of Directors.
  • "Their wealth of knowledge and industry experience will be instrumental in guiding Proniras through its next phase of growth.
  • We look forward to their leadership and contributions as we continue to advance Proniras through the next stages of product development."

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

Retrieved on: 
星期二, 十月 17, 2023
Health, Technology, Health Technology, Nanotechnology, Artificial Intelligence, Biotechnology, Vitae, Cyrus, IPD, Scripps Research, Drug development, Machine learning, Bristol Myers Squibb, Berkeley, Coronavirus Scientific Advisory Board, University, Artificial intelligence, Therapy, Affymetrix, Protein, Molecular biology, Cell biology, Drug discovery, ARCH Venture Partners, Harmon, Pharmaceutical industry, Vilya, Muller's morphs

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.

Key Points: 
  • VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.
  • “I am very excited to join the phenomenal team at Vilya developing new macrocycle drugs,” said Harmon.
  • Previously, Harmon co-founded and served as CEO of Olema Oncology, a company focused on women’s cancers, before transitioning to the role of Chief Research Officer.
  • Harmon joins Katerina Leftheris, Ph.D., Vilya’s Chief Scientific Officer on the company’s leadership team.

Vilya Launches to Design a New Transformational Class of Medicines That Precisely Target Disease Biology

Retrieved on: 
星期一, 八月 29, 2022
Research, Health Technology, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Machine learning, Research, Peptide, Antibody, Biology, Company, Institute, Drug development, IPD, Nature, Pharmaceutical industry, Fine chemical, Cell, Vilya

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced its launch today.

Key Points: 
  • VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, announced its launch today.
  • Vilya is co-founded by world-class scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners.
  • These capabilities position the Company to precisely target disease biology.
  • Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology.